Physician profile

Eric Mark J Lopez

Nephrology (Internal Medicine) · Hagerstown, MD

NPI 1942543954

$197.43

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$38.72
Education$10.55

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $55.46 2022
Astrazeneca Pharmaceuticals LP $27.16 2021-2022
Vifor Pharma, INC. $24.62 2021
Mallinckrodt Hospital Products INC. $24.18 2022
Novartis Pharmaceuticals Corporation $22.63 2024
Opko Pharmaceuticals, LLC $16.74 2020
Fresenius USA Marketing, INC. $16.09 2023 Velphoro
Travere Therapeutics, INC. $10.55 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eric Mark J Lopez

$197.43

in general payments reported 2019-2025

Years
2020-2024
Top company
Bayer Healthcare Pharmaceuticals INC.

https://glasscript.com/doctor/4226639/eric-mark-j-lopez

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.